Neurokinin 1 antagonist - Nippon-Roche

Drug Profile

Neurokinin 1 antagonist - Nippon-Roche

Alternative Names: NK-1 antagonist - Nippon-Roche

Latest Information Update: 31 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Class
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 31 Jul 2006 No development reported - Phase-I for Depression in Japan (unspecified route)
  • 30 Oct 2002 Nippon Roche has been merged into Chugai Pharmaceutical
  • 12 Jun 2002 Phase-I clinical trials in Depression in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top